NutriBand Q3 Revenue Plunges 35% to $433K as Key Customer Shifts Operations
NTRB is trading near its 52-week low of $3.209 (9.7% above the low).
Summary
NutriBand reported Q3 2026 revenue of $433K, a 35.1% year-over-year decline, driven by a key contract manufacturing customer shifting operations to Asia. The company posted a net loss of $1.24M, or $(0.10) EPS, which was a slight improvement from the prior year. This significant revenue drop highlights a material challenge in its core manufacturing business, despite the ongoing development of its AVERSA fentanyl product with Kindeva.
At the time of this announcement, NTRB was trading at $3.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $42.8M. The 52-week trading range was $3.21 to $11.68. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.